APD334

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
93Primary biliary cholangitis1
96Crohn disease32
97Ulcerative colitis89
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastro-intestinal disorder3
269Pyogenic arthritis1

93. Primary biliary cholangitis


Clinical trials : 352Drugs : 206 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 119 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,737Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 3,305Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

98. Eosinophilic gastro-intestinal disorder


Clinical trials : 214Drugs : 171 - (DrugBank : 46) / Drug target genes : 48 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

269. Pyogenic arthritis


Clinical trials : 32Drugs : 32 - (DrugBank : 16) / Drug target genes : 17 - Drug target pathways : 106 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries